BioWorld Asia

May 12, 2004

Arpida Raises CHF51.3M, Plans To Move Iclaprim Into Phase III

Arpida Ltd. raised CHF51.3 million (US$39.4 million) in a Series C funding round, bringing its total funding to date to CHF105 million. (BioWorld International) Read More

Faust Pharmaceuticals Closes EUR16M Second-Round Financing

Molecular Switch That Triggers Apoptosis Delivers Drug Target

Eirx Out-Licenses Apoptosis Targets To OSI In $18.8M Deal

Lectus Gets Investment From Takeda For PFD Protein Work

Report: 25 Recommendations For EU Strategies On Genetic Testing

Immatics Raises EUR8.5M In First Round Of Financing

Advanced Biotherapy Cross-Licenses IP With Innogenetics

Biota Holdings Suing GSK Over Support For Flu Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...